In the first peak, the upregulation of molecules with accessible targeted drugs, such as IL13RA1, IL13RA2, and TNFSF4,32 was more significant, suggesting the practicality of early intervention with targeted drugs to prevent the occurrence or exacerbation of AD after COVID-19 infection. Here, IL13RA2 is linked to Alzheimer disease.